All In Biotech

NDA 216185 · Aucta

Motpoly Xr

Lacosamide · Oral

Last checked: Nov 20, 2026Latest source record: Jun 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 4, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

96

41 Phase 3, 6 recruiting

FAERS reports

19,419

16,935 serious, 1,904 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 16, 2025.

MOTPOLY XR is indicated for: Treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and in pediatric patients weighing at least 50 kg (1.2) 1.1 Partial-Onset Seizures MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg. 1.2 Primary Generalized Tonic-Clonic Seizures MOTPOLY XR is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and in pediatric patients weighing at least 50 kg. Additional pediatric use information is approved for UCB Inc.'s Vimpat (lacosamide) tablets, oral solution, and intravenous solution. However, due to UCB Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Mechanism: The precise mechanism by which MOTPOLY XR exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • MOTPOLY XR · LACOSAMIDE 150MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • MOTPOLY XR · LACOSAMIDE 200MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • MOTPOLY XR · LACOSAMIDE 100MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lacosamide" as an intervention, any sponsor and status, largest first.

All 96 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure3,522
  • drug ineffective3,033
  • off label use2,359
  • status epilepticus811
  • dizziness741
  • drug interaction736
  • epilepsy720
  • fall716
  • somnolence701
  • generalised tonic-clonic seizure674
  • overdose652
  • multiple-drug resistance603

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
2009197
2010397
2011496
2012282
2013205
2014218
2015267
2016380
2017660
20181,320
20191,379
20201,326
20211,806
20221,896
20232,023
20242,509
20252,360
20261,697

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Motpoly XR (Lacosamide)

2024 spending

$394K

Beneficiaries

106

349 claims

Per beneficiary

$3,719

$20.11 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$394,240

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 192 on PubMed

Sponsor: Aucta

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.